Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

Vaccine

Volumn 28, Issue 2, 2009, Pages 484-493

  Bernstein, David I ^a   Reap, Elizabeth A ^b   Katen, Kevin ^b   Watson, Aubrey ^b   Smith, Kaitlin ^b   Norberg, Pamela ^b   Olmsted, Robert A ^b   Hoeper, Amy ^a   Morris, John ^b   Negri, Sarah ^b   Maughan, Maureen F ^b   Chulay, Jeffrey D ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b AlphaVax Inc   (United States)

Author keywords

Alphavirus replicon vaccine; Cellular immunity; Cytomegalovirus

Indexed keywords

ALPHAVIRUS REPLICON VACCINE; ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VACCINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; MODELS, BIOLOGICAL; T-LYMPHOCYTES; YOUNG ADULT;

EID: 70649091049     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.135     Document Type: Article

References (37)

1. High K.P. Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence. Clin Infect Dis 28 April (4) (1999) 746-749
2. Koch S., Larbi A., Ozcelik D., Solana R., Gouttefangeas C., Attig S., et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114 October (2007) 23-35
3. Newkirk M.M., van Venrooij W.J., and Marshall G.S. Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection. Arthritis Res 3 4 (2001) 253-258
4. Whitley R.J. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 549 (2004) 155-160
5. Adler S.P., and Marshall B. Cytomegalovirus infections. Pediatr Rev 28 March (3) (2007) 92-100
6. Arvin A.M., Fast P., Myers M., Plotkin S., and Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39 July (2) (2004) 233-239
7. Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317 October (17) (1987) 1049-1054
8. Falagas M.E., Snydman D.R., Ruthazer R., Griffith J., Werner B.G., Freeman R., et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 11 October (5 Pt 1) (1997) 432-437
9. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 October (16) (1995) 1038-1044
10. Nigro G., Adler S.P., La Torre R., and Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 September (13) (2005) 1350-1362
11. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., and Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326 March (10) (1992) 663-667
12. Britt W.J., Vugler L., and Stephens E.B. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol 62 September (9) (1988) 3309-3318
13. Speckner A., Glykofrydes D., Ohlin M., and Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 80 August (Pt 8) (1999) 2183-2191
14. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181 May (5) (2000) 1537-1546
15. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202 September (5) (2005) 673-685
16. Atkins G.J., Fleeton M.N., and Sheahan B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 10 (2008) e33
17. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22 January (3-4) (2004) 520-527
18. Durso R.J., Andjelic S., Gardner J.P., Margitich D.J., Donovan G.P., Arrigale R.R., et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 13 July (13) (2007) 3999-4008
19. Goldberg S.M., Bartido S.M., Gardner J.P., Guevara-Patino J.A., Montgomery S.C., Perales M.A., et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 11 November (22) (2005) 8114-8121
20. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25 November (48) (2007) 8180-8189
21. Nelson E.L., Prieto D., Alexander T.G., Pushko P., Lofts L.A., Rayner J.O., et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat 82 December (3) (2003) 169-183
22. Wang X., Wang J.P., Maughan M.F., and Lachman L.B. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res 7 1 (2005) R145-R155
23. Rayner J.O., Dryga S.A., and Kamrud K.I. Alphavirus vectors and vaccination. Rev Med Virol 12 September-October (5) (2002) 279-296
24. Reap E.A., Dryga S.A., Morris J., Rivers B., Norberg P.K., Olmsted R.A., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1 and gB proteins. Clin Vaccine Immunol April (2007)
25. Reap E.A., Morris J., Dryga S.A., Maughan M., Talarico T., Esch R.E., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25 October (42) (2007) 7441-7449
26. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171 January (1) (1995) 26-32
27. Plotkin S.A., Smiley M.L., Friedman H.M., Starr S.E., Fleisher G.R., Wlodaver C., et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1 March (8376) (1984) 528-530
28. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360 March (12) (2009) 1191-1199
29. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180 October (4) (1999) 970-975
30. Bernstein D.I., Schleiss M.R., Berencsi K., Gonczol E., Dickey M., Khoury P., et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185 March (5) (2002) 686-690
31. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180 September (3) (1999) 843-846
32. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 April (8) (2001) 1171-1179
33. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197 June (12) (2008) 1634-1642
34. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 April (4) (2008) 247-258
35. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., and Bernstein D.I. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 189 April (8) (2004) 1374-1381
36. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195 March (6) (2007) 789-798
37. Gonzalez Armas J.C., Morello C.S., Cranmer L.D., and Spector D.H. DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70 November (11) (1996) 7921-7928